Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
Total Valuation
Zealand Pharma has a market cap or net worth of $3.93B. The enterprise value is $20.79B.
Market Cap$3.93B
Enterprise Value$20.79B
Share Statistics
Zealand Pharma has 71,343,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,343,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zealand Pharma’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.89%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-13.89%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee162.83K
Profits Per Employee-2.80M
Employee Count385
Asset Turnover<0.01
Inventory Turnover0.74
Valuation Ratios
The current PE Ratio of Zealand Pharma is -44.06. Zealand Pharma’s PEG ratio is 0.80.
PE Ratio-44.06
PS Ratio0.00
PB Ratio11.40
Price to Fair Value5.52
Price to FCF-9.75
Price to Operating Cash Flow-9.88
PEG Ratio0.80
Income Statement
In the last 12 months, Zealand Pharma had revenue of 62.69M and earned -1.08B in profits. Earnings per share was -16.24.
Revenue62.69M
Gross Profit54.82M
Operating Income-1.27B
Pretax Income-1.08B
Net Income-1.08B
EBITDA-1.02B
Earnings Per Share (EPS)-16.24
Cash Flow
In the last 12 months, operating cash flow was -1.21B and capital expenditures -18.38M, giving a free cash flow of -1.23B billion.
Operating Cash Flow-1.21B
Free Cash Flow-1.23B
Free Cash Flow per Share-17.19
Dividends & Yields
Zealand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change-55.77%
50-Day Moving Average65.85
200-Day Moving Average93.92
Relative Strength Index (RSI)31.37
Average Volume (3m)834.00
Important Dates
Zealand Pharma upcoming earnings date is Aug 14, 2025, TBA (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 14, 2025
Ex-Dividend Date―
Financial Position
Zealand Pharma as a current ratio of 21.14, with Debt / Equity ratio of 54.35%
Current Ratio21.14
Quick Ratio21.11
Debt to Market Cap<0.01
Net Debt to EBITDA0.09
Interest Coverage Ratio-31.11
Taxes
In the past 12 months, Zealand Pharma has paid -4.62M in taxes.
Income Tax-4.62M
Effective Tax Rate<0.01
Enterprise Valuation
Zealand Pharma EV to EBITDA ratio is -46.67, with an EV/FCF ratio of -50.26.
EV to Sales756.81
EV to EBITDA-46.67
EV to Free Cash Flow-50.26
EV to Operating Cash Flow-50.97
Balance Sheet
Zealand Pharma has $8.54B in cash and marketable securities with kr394.64M in debt, giving a net cash position of -$8.15B billion.
Cash & Marketable Securities$8.54B
Total Debtkr394.64M
Net Cash-$8.15B
Net Cash Per Share-$114.23
Tangible Book Value Per Share$129.51
Margins
Gross margin is 70.47%, with operating margin of -2029.33%, and net profit margin of -1720.87%.
Gross Margin70.47%
Operating Margin-2029.33%
Pretax Margin-1728.23%
Net Profit Margin-1720.87%
EBITDA Margin-1621.76%
EBIT Margin-1673.92%
Analyst Forecast
The average price target for Zealand Pharma is $75.98, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$75.98
Price Target Upside35.73% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―